|
1
|
Center MM, Jemal A, Smith RA and Ward E:
Worldwide variations in colorectal cancer. CA Cancer J Clin.
59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kozomara A and Griffiths-Jones S: miRBase:
annotating high confidence microRNAs using deep sequencing data.
Nucleic Acids Res. 42:(Database Issue). D68–D73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grady WM and Tewari M: The next thing in
prognostic molecular markers: microRNA signatures of cancer. Gut.
59:706–708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goel A and Boland CR: Epigenetics of
colorectal cancer. Gastroenterology. 143:1442.e1–1460.e1. 2012.
View Article : Google Scholar
|
|
12
|
Schwarzenbach H, Nishida N, Calin GA and
Pantel K: Clinical relevance of circulating cell-free microRNAs in
cancer. Nat Rev Clin Oncol. 11:145–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Michael MZ, O'Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific microRNAs in colorectal neoplasia. Mol Cancer Res.
1:882–891. 2003.PubMed/NCBI
|
|
14
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rohr C, Kerick M, Fischer A, Kühn A,
Kashofer K, Timmermann B, Daskalaki A, Meinel T, Drichel D, Börno
ST, et al: High-throughput miRNA and mRNA sequencing of paired
colorectal normal, tumor and metastasis tissues and bioinformatic
modeling of miRNA-1 therapeutic applications. PLoS One.
8:e674612013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pencheva N and Tavazoie SF: Control of
metastatic progression by microRNA regulatory networks. Nat Cell
Biol. 15:546–554. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qian B, Nag SA, Su Y, Voruganti S, Qin JJ,
Zhang R and Cho WC: MiRNAs in cancer prevention and treatment and
as molecular targets for natural product anticancer agents. Curr
Cancer Drug Targets. 13:519–541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzuki HI, Katsura A, Matsuyama H and
Miyazono K: MicroRNA regulons in tumor microenvironment. Oncogene.
34:3085–3094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Berindan-Neagoe I, Pdel C Monroig,
Pasculli B and Calin GA: MicroRNAome genome: a treasure for cancer
diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hermeking H: MicroRNAs in the p53 network:
micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Giordano S and Columbano A: MicroRNAs: new
tools for diagnosis, prognosis and therapy in hepatocellular
carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weisenberger DJ: Characterizing DNA
methylation alterations from the cancer Genome Atlas. J Clin
Invest. 124:17–23. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue B and He L: An expanding universe of
the non-coding genome in cancer biology. Carcinogenesis.
35:1209–1216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ballestrero A, Garuti A, Cirmena G, Rocco
I, Palermo C, Nencioni A, Scabini S, Zoppoli G, Parodi S and
Patrone F: Patient-tailored treatments with anti-EGFR monoclonal
antibodies in advanced colorectal cancer: KRAS and beyond. Curr
Cancer Drug Targets. 12:316–328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kent OA, McCall MN, Cornish TC and
Halushka MK: Lessons from miR-143/145: the importance of cell-type
localization of miRNAs. Nucleic Acids Res. 42:7528–7538. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Segditsas S and Tomlinson I: Colorectal
cancer and genetic alterations in the Wnt pathway. Oncogene.
25:7531–7537. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma Y, Zhang P, Wang F, Zhang H, Yang Y,
Shi C, Xia Y, Peng J, Liu W, Yang Z and Qin H: Elevated oncofoetal
miR-17-5p expression regulates colorectal cancer progression by
repressing its target gene P130. Nat Commun. 3:12912012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Strillacci A, Valerii MC, Sansone P,
Caggiano C, Sgromo A, Vittori L, Fiorentino M, Poggioli G, Rizzello
F, Campieri M and Spisni E: Loss of miR-101 expression promotes
Wnt/β-catenin signalling pathway activation and malignancy in colon
cancer cells. J Pathol. 229:379–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vermeulen L, De Sousa E Melo F, van der
Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M,
Merz C, Rodermond H, et al: Wnt activity defines colon cancer stem
cells and is regulated by the microenvironment. Nat Cell Biol.
12:468–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Le Grand F, Jones AE, Seale V, Scimè A and
Rudnicki MA: Wnt7a activates the planar cell polarity pathway to
drive the symmetric expansion of satellite stem cells. Cell Stem
Cell. 4:535–547. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hwang WL, Jiang JK, Yang SH, Huang TS, Lan
HY, Teng HW, Yang CY, Tsai YP, Lin CH, Wang HW and Yang MH:
MicroRNA-146a directs the symmetric division of Snail-dominant
colorectal cancer stem cells. Nat Cell Biol. 16:268–280. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carstens JL, Lovisa S and Kalluri R:
Microenvironment-dependent cues trigger miRNA-regulated feedback
loop to facilitate the EMT/MET switch. J Clin Invest.
124:1458–1460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang JX, Mai SJ, Huang XX, Wang FW, Liao
YJ, Lin MC, Kung HF, Zeng YX and Xie D: MiR-29c mediates
epithelial-to-mesenchymal transition in human colorectal carcinoma
metastasis via PTP4A and GNA13 regulation of β-catenin signaling.
Ann Oncol. 25:2196–2204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rokavec M, Öner MG, Li H, Jackstadt R,
Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, et
al: IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated
colorectal cancer invasion and metastasis. J Clin Invest.
124:1853–1867. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen X, Guo X, Zhang H, Xiang Y, Chen J,
Yin Y, Cai X, Wang K, Wang G, Ba Y, et al: Role of miR-143
targeting KRAS in colorectal tumorigenesis. Oncogene. 28:1385–1392.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pagliuca A, Valvo C, Fabrizi E, di Martino
S, Biffoni M, Runci D, Forte S, De Maria R and Ricci-Vitiani L:
Analysis of the combined action of miR-143 and miR-145 on oncogenic
pathways in colorectal cancer cells reveals a coordinate program of
gene repression. Oncogene. 32:4806–4813. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsang WP and Kwok TT: The miR-18a*
microRNA functions as a potential tumor suppressor by targeting on
K-Ras. Carcinogenesis. 30:953–959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY,
Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, et al: MicroRNA-30b functions
as a tumour suppressor in human colorectal cancer by targeting
KRAS, PIK3CD and BCL2. J Pathol. 232:415–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sebio A, Paré L, Pàez D, Salazar J,
González A, Sala N, del Río E, Martín-Richard M, Tobeña M, Barnadas
A and Baiget M: The LCS6 polymorphism in the binding site of let-7
microRNA to the KRAS 3′-untranslated region: its role in the
efficacy of anti-EGFR-based therapy in metastatic colorectal cancer
patients. Pharmacogenet Genomics. 23:142–147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ota T, Doi K, Fujimoto T, Tanaka Y, Ogawa
M, Matsuzaki H, Kuroki M, Miyamoto S, Shirasawa S and Tsunoda T:
KRAS up-regulates the expression of miR-181a, miR-200c and miR-210
in a three-dimensional-specific manner in DLD-1 colorectal cancer
cells. Anticancer Res. 32:2271–2275. 2012.PubMed/NCBI
|
|
42
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lièvre A, Bachet JB, Boige V, Cayre A, Le
Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, et al: KRAS
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Manceau G, Imbeaud S, Thiébaut R, Liébaert
F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent
M, et al: Hsa-miR-31-3p expression is linked to progression-free
survival in patients with KRAS wild-type metastatic colorectal
cancer treated with anti-EGFR therapy. Clin Cancer Res.
20:3338–3347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saridaki Z, Weidhaas JB, Lenz HJ,
Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW,
Zhang W, Yang D, et al: A let-7 microRNA-binding site polymorphism
in KRAS predicts improved outcome in patients with metastatic
colorectal cancer treated with salvage cetuximab/panitumumab
monotherapy. Clin Cancer Res. 20:4499–4510. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pichler M, Winter E, Ress AL, Bauernhofer
T, Gerger A, Kiesslich T, Lax S, Samonigg H and Hoefler G: MiR-181a
is associated with poor clinical outcome in patients with
colorectal cancer treated with EGFR inhibitor. J Clin Pathol.
67:198–203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pichler M, Winter E, Stotz M, Eberhard K,
Samonigg H, Lax S and Hoefler G: Down-regulation of
KRAS-interacting miRNA-143 predicts poor prognosis but not response
to EGFR-targeted agents in colorectal cancer. Br J Cancer.
106:1826–1832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fabbri M and Calin GA: Epigenetics and
miRNAs in human cancer. Adv Genet. 70:87–99. 2010.PubMed/NCBI
|
|
49
|
Toyota M, Suzuki H, Sasaki Y, Maruyama R,
Imai K, Shinomura Y and Tokino T: Epigenetic silencing of
microRNA-34b/c and B-cell translocation gene 4 is associated with
CpG island methylation in colorectal cancer. Cancer Res.
68:4123–4132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vinci S, Gelmini S, Mancini I, Malentacchi
F, Pazzagli M, Beltrami C, Pinzani P and Orlando C: Genetic and
epigenetic factors in regulation of microRNA in colorectal cancers.
Methods. 59:138–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lujambio A, Ropero S, Ballestar E, Fraga
MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A,
Sanchez-Cespedes M, Git A, et al: Genetic unmasking of an
epigenetically silenced microRNA in human cancer cells. Cancer Res.
67:1424–1429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bandres E, Agirre X, Bitarte N, Ramirez N,
Zarate R, Roman-Gomez J, Prosper F and Garcia-Foncillas J:
Epigenetic regulation of microRNA expression in colorectal cancer.
Int J Cancer. 125:2737–2743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen WS, Leung CM, Pan HW, Hu LY, Li SC,
Ho MR and Tsai KW: Silencing of miR-1-1 and miR-133a-2 cluster
expression by DNA hypermethylation in colorectal cancer. Oncol Rep.
28:1069–1076. 2012.PubMed/NCBI
|
|
54
|
Suzuki H, Takatsuka S, Akashi H, Yamamoto
E, Nojima M, Maruyama R, Kai M, Yamano HO, Sasaki Y, Tokino T, et
al: Genome-wide profiling of chromatin signatures reveals
epigenetic regulation of MicroRNA genes in colorectal cancer.
Cancer Res. 71:5646–5658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Deng G, Kakar S and Kim YS: MicroRNA-124a
and microRNA-34b/c are frequently methylated in all histological
types of colorectal cancer and polyps and in the adjacent normal
mucosa. Oncol Lett. 2:175–180. 2011.PubMed/NCBI
|
|
56
|
Ueda Y, Ando T, Nanjo S, Ushijima T and
Sugiyama T: DNA methylation of microRNA-124a is a potential risk
marker of colitis-associated cancer in patients with ulcerative
colitis. Dig Dis Sci. 59:2444–2451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Grady WM, Parkin RK, Mitchell PS, Lee JH,
Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz
AM, et al: Epigenetic silencing of the intronic microRNA
hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene.
27:3880–3888. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Balaguer F, Link A, Lozano JJ, Cuatrecasas
M, Nagasaka T, Boland CR and Goel A: Epigenetic silencing of
miR-137 is an early event in colorectal carcinogenesis. Cancer Res.
70:6609–6618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yan H, Choi AJ, Lee BH and Ting AH:
Identification and functional analysis of epigenetically silenced
microRNAs in colorectal cancer cells. PLoS One. 6:e206282011.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Humphreys KJ, Cobiac L, Le Leu RK, Van der
Hoek MB and Michael MZ: Histone deacetylase inhibition in
colorectal cancer cells reveals competing roles for members of the
oncogenic miR-17–92 cluster. Mol Carcinog. 52:459–474. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Siemens H, Neumann J, Jackstadt R,
Mansmann U, Horst D, Kirchner T and Hermeking H: Detection of
miR-34a promoter methylation in combination with elevated
expression of c-Met and β-catenin predicts distant metastasis of
colon cancer. Clin Cancer Res. 19:710–720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Takahashi Y, Iwaya T, Sawada G, Kurashige
J, Matsumura T, Uchi R, Ueo H, Takano Y, Eguchi H, Sudo T, et al:
Up-regulation of NEK2 by microRNA-128 methylation is associated
with poor prognosis in colorectal cancer. Ann Surg Oncol.
21:205–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sun J, Song Y, Wang Z, Wang G, Gao P, Chen
X, Gao Z and Xu H: Clinical significance of promoter region
hypermethylation of microRNA-148a in gastrointestinal cancers. Onco
Targets Ther. 7:853–863. 2014.PubMed/NCBI
|
|
64
|
Cho WC: Epigenetic alteration of microRNAs
in feces of colorectal cancer and its clinical significance. Expert
Rev Mol Diagn. 11:691–694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang Y, Wang X, Xu B, Wang B, Wang Z,
Liang Y, Zhou J, Hu J and Jiang B: Epigenetic silencing of miR-126
contributes to tumor invasion and angiogenesis in colorectal
cancer. Oncol Rep. 30:1976–1984. 2013.PubMed/NCBI
|
|
66
|
Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z,
Chen Z, Qiu F, Xu J and Huang J: miRNA-27b targets vascular
endothelial growth factor C to inhibit tumor progression and
angiogenesis in colorectal cancer. PLoS One. 8:e606872013.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang F, Ma YL, Zhang P, Shen TY, Shi CZ,
Yang YZ, Moyer MP, Zhang HZ, Chen HQ, Liang Y and Qin HL: SP1
mediates the link between methylation of the tumour suppressor
miR-149 and outcome in colorectal cancer. J Pathol. 229:12–24.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Menigatti M, Staiano T, Manser CN,
Bauerfeind P, Komljenovic A, Robinson M, Jiricny J, Buffoli F and
Marra G: Epigenetic silencing of monoallelically methylated miRNA
loci in precancerous colorectal lesions. Oncogenesis. 2:e562013.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Meng X, Wu J, Pan C, Wang H, Ying X, Zhou
Y, Yu H, Zuo Y, Pan Z, Liu RY and Huang W: Genetic and epigenetic
down-regulation of microRNA-212 promotes colorectal tumor
metastasis via dysregulation of MnSOD. Gastroenterology.
145:426–436.e1-e6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hur K, Toiyama Y, Takahashi M, Balaguer F,
Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tang JT, Wang JL, Du W, Hong J, Zhao SL,
Wang YC, Xiong H, Chen HM and Fang JY: MicroRNA 345, a
methylation-sensitive microRNA is involved in cell proliferation
and invasion in human colorectal cancer. Carcinogenesis.
32:1207–1215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Tanaka T, Arai M, Wu S, Kanda T, Miyauchi
H, Imazeki F, Matsubara H and Yokosuka O: Epigenetic silencing of
microRNA-373 plays an important role in regulating cell
proliferation in colon cancer. Oncol Rep. 26:1329–1335.
2011.PubMed/NCBI
|
|
73
|
Hinoue T, Weisenberger DJ, Lange CP, Shen
H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk
CM, et al: Genome-scale analysis of aberrant DNA methylation in
colorectal cancer. Genome Res. 22:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Weber B, Stresemann C, Brueckner B and
Lyko F: Methylation of human microRNA genes in normal and
neoplastic cells. Cell Cycle. 6:1001–1005. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Christman JK: 5-Azacytidine and
5-aza-2′-deoxycytidine as inhibitors of DNA methylation:
mechanistic studies and their implications for cancer therapy.
Oncogene. 21:5483–5495. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ceppi P, Mudduluru G, Kumarswamy R, Rapa
I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c
expression induces an aggressive, invasive and chemoresistant
phenotype in non-small cell lung cancer. Mol Cancer Res.
8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Vrba L, Jensen TJ, Garbe JC, Heimark RL,
Cress AE, Dickinson S, Stampfer MR and Futscher BW: Role for DNA
methylation in the regulation of miR-200c and miR-141 expression in
normal and cancer cells. PLoS One. 5:e86972010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt
L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS,
Borre M, et al: Coordinated epigenetic repression of the miR-200
family and miR-205 in invasive bladder cancer. Int J Cancer.
128:1327–1334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Davalos V, Moutinho C, Villanueva A, Boque
R, Silva P, Carneiro F and Esteller M: Dynamic epigenetic
regulation of the microRNA-200 family mediates epithelial and
mesenchymal transitions in human tumorigenesis. Oncogene.
31:2062–2074. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Hartnett L and Egan LJ: Inflammation, DNA
methylation and colitis-associated cancer. Carcinogenesis.
33:723–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Valeri N, Braconi C, Gasparini P, Murgia
C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat
F, et al: MicroRNA-135b promotes cancer progression by acting as a
downstream effector of oncogenic pathways in colon cancer. Cancer
Cell. 25:469–483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wu CW, Ng SC, Dong Y, Tian L, Ng SS, Leung
WW, Law WT, Yau TO, Chan FK, Sung JJ and Yu J: Identification of
microRNA-135b in stool as a potential noninvasive biomarker for
colorectal cancer and adenoma. Clin Cancer Res. 20:2994–3002. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Kanaan Z, Rai SN, Eichenberger MR, Barnes
C, Dworkin AM, Weller C, Cohen E, Roberts H, Keskey B, Petras RE,
et al: Differential microRNA expression tracks neoplastic
progression in inflammatory bowel disease-associated colorectal
cancer. Hum Mutat. 33:551–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Koukos G, Polytarchou C, Kaplan JL,
Morley-Fletcher A, Gras-Miralles B, Kokkotou E, Baril-Dore M,
Pothoulakis C, Winter HS and Iliopoulos D: MicroRNA-124 regulates
STAT3 expression and is down-regulated in colon tissues of
pediatric patients with ulcerative colitis. Gastroenterology.
145:842–852 e2. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Johnson CD, Esquela-Kerscher A, Stefani G,
Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J,
Shingara J, et al: The let-7 microRNA represses cell proliferation
pathways in human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang F, Zhang P, Ma Y, Yang J, Moyer MP,
Shi C, Peng J and Qin H: NIRF is frequently upregulated in
colorectal cancer and its oncogenicity can be suppressed by let-7a
microRNA. Cancer Lett. 314:223–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Brueckner B, Stresemann C, Kuner R, Mund
C, Musch T, Meister M, Sültmann H and Lyko F: The human let-7a-3
locus contains an epigenetically regulated microRNA gene with
oncogenic function. Cancer Res. 67:1419–1423. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kouzarides T: Chromatin modifications and
their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hu S, Dong TS, Dalal SR, Wu F, Bissonnette
M, Kwon JH and Chang EB: The microbe-derived short chain fatty acid
butyrate targets miRNA-dependent p21 gene expression in human colon
cancer. PLoS One. 6:e162212011. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Shin S, Lee EM, Cha HJ, Bae S, Jung JH,
Lee SM, Yoon Y, Lee H, Kim S, Kim H, et al: MicroRNAs that respond
to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon
carcinoma cells. Int J Oncol. 35:1343–1352. 2009.PubMed/NCBI
|
|
91
|
Falkenberg KJ and Johnstone RW: Histone
deacetylases and their inhibitors in cancer, neurological diseases
and immune disorders. Nat Rev Drug Discov. 13:673–691. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Rada-Iglesias A, Enroth S, Ameur A, Koch
CM, Clelland GK, Respuela-Alonso P, Wilcox S, Dovey OM, Ellis PD,
Langford CF, et al: Butyrate mediates decrease of histone
acetylation centered on transcription start sites and
down-regulation of associated genes. Genome Res. 17:708–719. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Jeltsch A: Beyond Watson and Crick: DNA
methylation and molecular enzymology of DNA methyltransferases.
Chembiochem. 3:274–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Borralho PM, Kren BT, Castro RE, da Silva
IB, Steer CJ and Rodrigues CM: MicroRNA-143 reduces viability and
increases sensitivity to 5-fluorouracil in HCT116 human colorectal
cancer cells. FEBS J. 276:6689–6700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhang Y, Wang Z, Chen M, Peng L, Wang X,
Ma Q, Ma F and Jiang B: MicroRNA-143 targets MACC1 to inhibit cell
invasion and migration in colorectal cancer. Mol Cancer. 11:232012.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Gregersen LH, Jacobsen A, Frankel LB, Wen
J, Krogh A and Lund AH: MicroRNA-143 down-regulates Hexokinase 2 in
colon cancer cells. BMC Cancer. 12:2322012. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Qian X, Yu J, Yin Y, He J, Wang L, Li Q,
Zhang LQ, Li CY, Shi ZM, Xu Q, et al: MicroRNA-143 inhibits tumor
growth and angiogenesis and sensitizes chemosensitivity to
oxaliplatin in colorectal cancers. Cell Cycle. 12:1385–1394. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li
JJ, Röcken C, Ebert MP, Kwok TT and Sung JJ: MicroRNA-143 targets
DNA methyltransferases 3A in colorectal cancer. Br J Cancer.
101:699–706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Wang H, Wu J, Meng X, Ying X, Zuo Y, Liu
R, Pan Z, Kang T and Huang W: MicroRNA-342 inhibits colorectal
cancer cell proliferation and invasion by directly targeting DNA
methyltransferase 1. Carcinogenesis. 32:1033–1042. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Yeung F, Hoberg JE, Ramsey CS, Keller MD,
Jones DR, Frye RA and Mayo MW: Modulation of NF-kappaB-dependent
transcription and cell survival by the SIRT1 deacetylase. EMBO J.
23:2369–2380. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kriegl L, Vieth M, Kirchner T and Menssen
A: Up-regulation of c-MYC and SIRT1 expression correlates with
malignant transformation in the serrated route to colorectal
cancer. Oncotarget. 3:1182–1193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Yamakuchi M, Ferlito M and Lowenstein CJ:
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci
USA. 105:13421–13426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Kaller M, Liffers ST, Oeljeklaus S,
Kuhlmann K, Röh S, Hoffmann R, Warscheid B and Hermeking H:
Genome-wide characterization of miR-34a induced changes in protein
and mRNA expression by a combined pulsed SILAC and microarray
analysis. Mol Cell Proteomics. 10:M111.010462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Padi SK, Zhang Q, Rustum YM, Morrison C
and Guo B: MicroRNA-627 mediates the epigenetic mechanisms of
vitamin D to suppress proliferation of human colorectal cancer
cells and growth of xenograft tumors in mice. Gastroenterology.
145:437–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dou L, Zheng D, Li J, Li Y, Gao L, Wang L
and Yu L: Methylation-mediated repression of microRNA-143 enhances
MLL-AF4 oncogene expression. Oncogene. 31:507–517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing
C and Liu Z: Altered expression of MiR-148a and MiR-152 in
gastrointestinal cancers and its clinical significance. J
Gastrointest Surg. 14:1170–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Pavicic W, Perkiö E, Kaur S and Peltomäki
P: Altered methylation at microRNA-associated CpG islands in
hereditary and sporadic carcinomas: a methylation-specific
multiplex ligation-dependent probe amplification (MS-MLPA)-based
approach. Mol Med. 17:726–735. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Takahashi M, Cuatrecasas M, Balaguer F,
Hur K, Toiyama Y, Castells A, Boland CR and Goel A: The clinical
significance of MiR-148a as a predictive biomarker in patients with
advanced colorectal cancer. PLoS One. 7:e466842012. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhu A, Xia J, Zuo J, Jin S, Zhou H, Yao L,
Huang H and Han Z: MicroRNA-148a is silenced by hypermethylation
and interacts with DNA methyltransferase 1 in gastric cancer. Med
Oncol. 29:2701–2709. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar : PubMed/NCBI
|
